SEC Comment Letter for Vincerx Pharma, Inc. (VINC) (CIK 0001796129) (VINC) — Jan 25, 2022
Vincerx Pharma, Inc. (VINC) (CIK 0001796129)
Date: Jan. 25, 2022 · CIK: 0001796129 · Accession: 0000000000-22-000995
AI Filing Summary & Sentiment
File numbers found in text: 333-262239
Letter
United States securities and exchange commission logo January 25, 2022 Ahmed M. Hamdy Chief Executive Officer Vincerx Pharma, Inc. 260 Sheridan Avenue, Suite 400 Palo Alto, CA 94306 Re:Vincerx Pharma, Inc. Registration Statement on Form S-3 Filed January 19, 2022 File No. 333-262239 Dear Dr. Hamdy: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Gabriella Lombardi, Esq.
Show Raw Text
United States securities and exchange commission logo
January 25, 2022
Ahmed M. Hamdy
Chief Executive Officer
Vincerx Pharma, Inc.
260 Sheridan Avenue, Suite 400
Palo Alto, CA 94306
Re:Vincerx Pharma, Inc.
Registration Statement on Form S-3
Filed January 19, 2022
File No. 333-262239
Dear Dr. Hamdy:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Gabriella Lombardi, Esq.